232 related articles for article (PubMed ID: 31262348)
21. Clinic and Home Blood Pressure Lowering Effect of an Angiotensin Receptor Blocker, Fimasartan, in Postmenopausal Women with Hypertension.
Kim SY; Joo SJ; Shin MS; Kim C; Cho EJ; Sung KC; Kang SM; Kim DS; Lee SH; Hwang KK; Park JB
Medicine (Baltimore); 2016 May; 95(22):e3764. PubMed ID: 27258507
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and Safety Assessment of Hypertension Management with Coveram (Perindopril/Amlodipine Fixed Combination) in Patients with Previous Angiotensin Receptor Blocker (ARB) Treatment: Arabian Gulf STRONG Study.
Ahmed M; Alanbaei M; El Tamimi H; Al-Wahshi Y; Al-Zakwani I
Curr Vasc Pharmacol; 2016; 14(6):570-575. PubMed ID: 27456109
[TBL] [Abstract][Full Text] [Related]
23. Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.
Park JB; Sung KC; Kang SM; Cho EJ
Am J Cardiovasc Drugs; 2013 Feb; 13(1):47-56. PubMed ID: 23344912
[TBL] [Abstract][Full Text] [Related]
24. Comparative review of the blood pressure-lowering and cardiovascular benefits of telmisartan and perindopril.
Wang JG; Pimenta E; Chwallek F
Vasc Health Risk Manag; 2014; 10():189-200. PubMed ID: 24741317
[TBL] [Abstract][Full Text] [Related]
25. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
[TBL] [Abstract][Full Text] [Related]
26. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
[TBL] [Abstract][Full Text] [Related]
27. Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
Bulitta JB; Paik SH; Chi YH; Kim TH; Shin S; Landersdorfer CB; Jiao Y; Yadav R; Shin BS
Eur J Pharm Sci; 2017 Sep; 107():32-44. PubMed ID: 28599987
[TBL] [Abstract][Full Text] [Related]
28. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
[TBL] [Abstract][Full Text] [Related]
29. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
Lacourcière Y
Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232
[TBL] [Abstract][Full Text] [Related]
30. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
[TBL] [Abstract][Full Text] [Related]
31. Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study.
Mourad JJ; Lameira D; Guillausseau PJ
Vasc Health Risk Manag; 2008; 4(2):443-51. PubMed ID: 18561520
[TBL] [Abstract][Full Text] [Related]
32. A comparison between diuretics and angiotensin-receptor blocker agents in patients with stage I hypertension (PREVER-treatment trial): study protocol for a randomized double-blind controlled trial.
Fuchs FD; Fuchs SC; Moreira LB; Gus M; Nóbrega AC; Poli-de-Figueiredo CE; Mion D; Bortolotto L; Consolim-Colombo F; Nobre F; Coelho EB; Vilela-Martin JF; Moreno H; Cesarino EJ; Franco R; Brandão AA; de Sousa MR; Ribeiro AL; Jardim PC; Afiune Neto A; Scala LC; Mota M; Chaves H; Alves JG; Sobral Filho DC; Pereira e Silva R; Figueiredo Neto JA; Irigoyen MC; Castro I; Steffens AA; Schlatter R; de Mello RB; Mosele F; Ghizzoni F; Berwanger O
Trials; 2011 Feb; 12():53. PubMed ID: 21349192
[TBL] [Abstract][Full Text] [Related]
33. Fimasartan: A New Angiotensin Receptor Blocker.
Lee HY; Oh BH
Drugs; 2016 Jul; 76(10):1015-22. PubMed ID: 27272555
[TBL] [Abstract][Full Text] [Related]
34. Fimasartan reduces clinic and home pulse pressure in elderly hypertensive patients: A K-MetS study.
Cho EJ; Sung KC; Kang SM; Shin MS; Joo SJ; Park JB
PLoS One; 2019; 14(4):e0214293. PubMed ID: 30964905
[TBL] [Abstract][Full Text] [Related]
35. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals].
Weisser B; Gerwe M; Braun M; Funken C
Arzneimittelforschung; 2005; 55(9):505-13. PubMed ID: 16229114
[TBL] [Abstract][Full Text] [Related]
36. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
Chrysant SG; Neutel JM; Ferdinand KC;
J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
[TBL] [Abstract][Full Text] [Related]
37. Fixed low-dose combination therapy in hypertension--a dose response study of perindopril and indapamide.
Myers MG; Asmar R; Leenen FH; Safar M
J Hypertens; 2000 Mar; 18(3):317-25. PubMed ID: 10726719
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial.
Sohn IS; Kim CJ; Ahn T; Youn HJ; Jeon HK; Ihm SH; Cho EJ; Chung WB; Chae SC; Kim WS; Nam CW; Park SM; Choi JY; Kim YK; Hong TJ; Lee HY; Cho JH; Shin ES; Yoon JH; Yang TH; Jeong MH; Lee JH; Park JI
Clin Ther; 2017 Aug; 39(8):1628-1638. PubMed ID: 28734660
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme.
Pella D
High Blood Press Cardiovasc Prev; 2011 Sep; 18(3):107-13. PubMed ID: 21950782
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of fimasartan in Mexican patients with grade 1-2 essential hypertension.
Cardona-Muñoz EG; López-Alvarado A; Conde-Carmona I; Sánchez-Mejorada G; Pascoe-González S; Banda-Elizondo RG; García-Castillo A; González-Gálvez G; Velasco-Sánchez RG; Vidrio-Velázquez M; Leiva-Pons JL; Villeda-Espinosa E; Guerra-López A; Esturau-Santalo RM
Arch Cardiol Mex; 2017; 87(4):316-325. PubMed ID: 28209359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
